MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
45.32
+1.64
+3.75%
Opening 11:10 01/07 EST
OPEN
44.25
PREV CLOSE
43.68
HIGH
45.44
LOW
44.04
VOLUME
517.66K
TURNOVER
--
52 WEEK HIGH
49.62
52 WEEK LOW
31.90
MARKET CAP
12.15B
P/E (TTM)
19.08
1D
5D
1M
3M
1Y
5Y
1D
Natera to work with Exelixis on latter's zanzalintinib phase 3 trial
Seeking Alpha · 10h ago
Exelixis, Natera announce collaboration on STELLAR-316 trial
TipRanks · 11h ago
Exelixis and Natera Announce Collaboration on Phase 3 Colorectal Cancer Trial
Reuters · 12h ago
EXELIXIS INC - EXPECTS TO INITIATE STELLAR-316 IN MID-2026
Reuters · 12h ago
How Investors May Respond To Exelixis (EXEL) Pipeline Updates Amid Cabometyx Exclusivity and Competition Concerns
Simply Wall St · 13h ago
Exelixis CEO to Present Corporate Overview at J.P. Morgan Healthcare Conference
Reuters · 1d ago
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
Barchart · 1d ago
Exelixis cut to Underperform at BofA on valuation and lack of catalysts
Seeking Alpha · 2d ago
More
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.